Pulmonary Hypertension | Treatment Algorithms: Claims Data Analysis | Pulmonary Arterial Hypertension | US | 2021

Pulmonary arterial hypertension (PAH) is a rare, life-threatening disorder characterized by high blood pressure in the arteries of the lungs. It is a progressive condition marked by considerable morbidity and mortality. A wide array of drugs are available to treat PAH in the U.S. market. Phosphodiesterase 5 (PDE-5) inhibitors and endothelin receptor antagonists (ERAs) are the most commonly prescribed first-line treatments; the more-efficacious prostacyclin therapies are used in later lines. Branded therapies feature highly in the PAH treatment algorithm, and combination therapy is common. Using a longitudinal claims data analysis, we demonstrate how newly diagnosed and recently treated PAH patients receive pharmacotherapy the United States.


  • What patient shares do key therapies and brands garner by line of therapy in newly diagnosed PAH patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed PAH patients?
  • How are Uptravi, Orenitram, Opsumit, and Adempas integrated into the treatment algorithm, and what is their source of business?
  • What percentage of PAH patients receive drug therapy within two years of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within two years of diagnosis?
  • What percentage of PAH patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
  • What are the product-level compliance and persistency rates among drug-treated patients?


Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

Markets covered: United States

Key companies: United Therapeutics, Actelion, Pfizer, Bayer, Gilead

Key drugs: Adcirca, Opsumit, Tyvaso, Ventavis, Orenitram, Uptravi, Remodulin, Adempas, ambrisentan, bosentan, sildenafil, epoprostenol

Login to access report

launch Related Market Assessment Reports